Ergomed plc Result of General Meeting (4731C)

TIDMERGO

RNS Number : 4731C

Ergomed plc

19 October 2020

Ergomed Plc

Result of General Meeting

Guildford, UK - 19 October 2020 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that at its General Meeting held today the special resolutions regarding the proposed Capital Reduction were passed with 100% shareholder approval (see table and notes below).

The Capital Reduction remains subject to the Court's approval and a directions hearing is scheduled for 28 October 2020. If the Court is satisfied that the application should proceed, a second hearing will be held on 10 November 2020 to confirm the Capital Reduction.

A further announcement will be made following the Capital Reduction becoming effective.

Terms used but not defined in this announcement are as defined in the Company's announcement of 1 October 2020.

Details of the voting in respect of each resolution are shown in the table below:

 
                                           For                Against          Withheld 
 Resolution                        No. of Shares    %    No. of Shares   %   No. of Shares 
                                  --------------  ----  --------------      -------------- 
 1. To cancel the Company's 
  Share Premium Account             41,339,888     100       2,000       0       1,414 
                                  --------------  ----  --------------      -------------- 
 2. To capitalise the Company's 
  Merger Reserve by paying up 
  B Shares                          41,339,888     100        Nil        0       3,414 
                                  --------------  ----  --------------      -------------- 
 3. To cancel the B Shares          41,339,888     100        Nil        0       3,414 
                                  --------------  ----  --------------      -------------- 
 

Notes:

   1.     Votes "For" and "Against" are expressed as a percentage of votes received. 

2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

   3.     Percentages in relation to Resolution 1 are rounded. 

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: [phone] 
                                                                         975 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
 
 Numis Securities Limited                          Tel: [phone] 
 Freddie Barnfield / Huw Jeremy (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for          Tel: [phone] 
  UK enquiries 
 Chris Gardner / Sue Stuart                      [e-mail] 
 Matthew Neal / Olivia Manser 
 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMGCBDGCGBDGGC

(END) Dow Jones Newswires

October 19, 2020 05:12 ET (09:12 GMT)